August 22, 2019 / 10:17 AM / a month ago

Retrophin neurological disorder drug misses late-stage study main goal

Aug 22 (Reuters) - Retrophin Inc said on Thursday its treatment for a rare neurological disorder failed to meet the main goal in a late-stage study.

The treatment, fosmetpantotenate, was being tested in 84 patients with pantothenate kinase-associated neurodegeneration, a rare, genetic and life-threatening disorder.

The treatment, tested against placebo, also failed to meet its secondary goal, the company said. (Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Shinjini Ganguli)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below